# EDGAR Filing Document

**Accession Number:** 0001933414
**File Stem:** 0001628280-23-005045
**Filing Date:** 2023-2
**Character Count:** 22773
**Document Hash:** 3f619330aeb3c3cb986916aedf25f267
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-005045.hdr.sgml**: 20230224

**ACCESSION NUMBER**: 0001628280-23-005045

**CONFORMED SUBMISSION TYPE**: SC 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230224

**DATE AS OF CHANGE**: 20230224

**GROUP MEMBERS**: BIODISCOVERY 6 FPCI

**GROUP MEMBERS**: LAURENT TOURTOIS

**GROUP MEMBERS**: RAPHAEL WISNIEWSKI

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-94000
- **FILM NUMBER:** 23666883

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Andera Partners
- **CENTRAL INDEX KEY:** 0001757283
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G

**BUSINESS ADDRESS:**
- **STREET 1:** 374 RUE SAINT ST HONORE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75001
- **BUSINESS PHONE:** 33-1-85-73-6603

**MAIL ADDRESS:**
- **STREET 1:** 374 RUE SAINT ST HONORE
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75001

**Securities and Exchange Commission**

**Washington, D.C. 20549**

**Schedule 13G**

**(Rule 13d-102)**

**Information to be Included in Statements Filed Pursuant**

**to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed**

**Pursuant to § 240.13d-2**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

(Amendment No.)\*

**Mineralys Therapeutics, Inc.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**603170101**

(CUSIP Number)

**February 14, 2023**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

[&nbsp;&nbsp;&nbsp;&nbsp; ] Rule 13d-1(b)

[ X ] Rule 13d-1(c)

[&nbsp;&nbsp;&nbsp;&nbsp; ] Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 1 of 8</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons<br>**BioDiscovery 6 FPCI** | Names of Reporting Persons<br>**BioDiscovery 6 FPCI** | Names of Reporting Persons<br>**BioDiscovery 6 FPCI** |  |
| 2 | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ]<br>(b) [ ] |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only |  |
| 4 | Citizenship or Place of Organization<br>**France** | Citizenship or Place of Organization<br>**France** | Citizenship or Place of Organization<br>**France** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power <br>**2,865,976** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power <br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power <br>**2,865,976** |  |
| 9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** |  |
| 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** |  |
| 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** |  |
| 12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** |  |

---

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 2 of 8</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons<br>**Andera Partners** | Names of Reporting Persons<br>**Andera Partners** | Names of Reporting Persons<br>**Andera Partners** |  |
| 2 | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ]<br>(b) [ ] |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only |  |
| 4 | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power <br>**2,865,976** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power <br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power <br>**2,865,976** |  |
| 9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** |  |
| 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** |  |
| 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** |  |
| 12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**OO** |  |

---

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 3 of 8</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons<br>**Raphaël Wisniewski** | Names of Reporting Persons<br>**Raphaël Wisniewski** | Names of Reporting Persons<br>**Raphaël Wisniewski** |  |
| 2 | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ]<br>(b) [ ] |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only |  |
| 4 | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power <br>**2,865,976** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power <br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power <br>**2,865,976** |  |
| 9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** |  |
| 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** |  |
| 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** |  |
| 12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** |  |

---

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 4 of 8</u>

---

| | | | | |
|:---|:---|:---|:---|:---|
| 1 | Names of Reporting Persons<br>**Laurent Tourtois** | Names of Reporting Persons<br>**Laurent Tourtois** | Names of Reporting Persons<br>**Laurent Tourtois** |  |
| 2 | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | Check the Appropriate Box if a Member of a Group | (a) [ ]<br>(b) [ ] |
| 3 | SEC Use Only | SEC Use Only | SEC Use Only |  |
| 4 | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** | Citizenship or Place of Organization <br>**France** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Voting Power<br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Voting Power <br>**2,865,976** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 7 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sole Dispositive Power <br>**0** |  |
| Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | Number of Shares <br>Beneficially Owned <br>by Each Reporting <br>Person With | 8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shared Dispositive Power <br>**2,865,976** |  |
| 9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Aggregate Amount Beneficially Owned by Each Reporting Person <br>**2,865,976** |  |
| 10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check if the Aggregate Amount in Row (9) Excludes Certain Shares <br>**Not Applicable** |  |
| 11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percent of Class Represented by Amount in Row 9<br>**7.0%** |  |
| 12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type of Reporting Person <br>**IN** |  |

---

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 5 of 8</u>

**ITEM 1. (a)Name of Issuer:**

Mineralys Therapeutics, Inc. (the "Issuer").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)Address of Issuer's Principal Executive Offices:**

150 N. Radnor Chester Road, Suite F200

Radnor, Pennsylvania 19087

**ITEM 2. (a)Name of Person Filing:**

Each of the following is hereinafter individually referred to as a "Reporting Person" and collectively as the "Reporting Persons." This statement is filed on behalf of:

BioDiscovery 6 FPCI

Andera Partners

Raphaël Wisniewski

Laurent Tourtois

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)Address or Principal Business Office:**

The principal business address of each of the Reporting Persons is 2 Place Rio de Janeiro – 75008 Paris (France).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)Citizenship of each Reporting Person is:**

BioDiscovery 6 FPCI is organized under the laws of France. Andera Partners is organized under the laws of France. Raphaël Wisniewski is a citizen of France. Laurent Tourtois is a citizen of France.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)Title of Class of Securities:**

Common stock, par value $0.0001 per share ("Common Stock").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)CUSIP Number:**

603170101

**ITEM 3.**

Not applicable.

**ITEM 4. Ownership**

**(a-c)**

The ownership information presented below represents beneficial ownership of Common Stock of the Issuer as of the date hereof, based upon 40,856,653

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 6 of 8</u>

shares of Common Stock outstanding as of February 14, 2023, as provided by the Issuer.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Reporting Person** | **Amount**<br>**beneficially**<br>**owned** | **Percent**<br>**of class:** | **Sole power to vote or to direct the vote:** | **Shared power to vote or to direct the vote:** | **Sole power to dispose or to** <br>**direct the disposition**<br>**of:** | **Shared**<br>**power to**<br>**dispose or**<br>**to direct**<br>**the**<br>**disposition**<br>**of:** |
| BioDiscovery 6 FPCI | 2865976 | 7.0% | 0 | 2865976 | 0 | 2865976 |
| Andera Partners | 2865976 | 7.0% | 0 | 2865976 | 0 | 2865976 |
| Raphaël Wisniewski | 2865976 | 7.0% | 0 | 2865976 | 0 | 2865976 |
| Laurent Tourtois | 2865976 | 7.0% | 0 | 2865976 | 0 | 2865976 |

---

BioDiscovery 6 FPCI is the record holder of the shares of Common Stock reported herein. Voting and dispositive decisions with respect to the securities held by BioDiscovery 6 FPCI are made by its management company, Andera Partners. The managing partners of Andera Partners consist of Raphaël Wisniewski and Laurent Tourtois. As a result, each of the Reporting Persons may be deemed to beneficially own the securities held by BioDiscovery 6 FPCI.

**ITEM 5. Ownership of Five Percent or Less of a Class.**

Not applicable.

**ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not applicable.

**ITEM 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable.

**ITEM 8. Identification and Classification of Members of the Group.**

Not applicable.

**ITEM 9. Notice of Dissolution of Group.**

Not applicable.

**ITEM 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 7 of 8</u>

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | | |
|:---|:---|:---|:---|
| **Date:** | February 24, 2023 |  |  |
|  |  | **BioDiscovery 6 FPCI** | **BioDiscovery 6 FPCI** |
|  |  | By: Andera Partners, its management company | By: Andera Partners, its management company |
|  |  | By: | /s/ Raphaël Wisniewski |
|  |  | Name: | Raphaël Wisniewski |
|  |  | Title: | Managing Partner |
|  |  | **Andera Partners** | **Andera Partners** |
|  |  | By: | /s/ Raphaël Wisniewski |
|  |  | Name: | Raphaël Wisniewski |
|  |  | Title: | Managing Partner |
|  |  | **Raphaël Wisniewski** | **Raphaël Wisniewski** |
|  |  | /s/ Raphaël Wisniewski | /s/ Raphaël Wisniewski |
|  |  | **Laurent Tourtois** | **Laurent Tourtois** |
|  |  | /s/ Laurent Tourtois | /s/ Laurent Tourtois |

---

------

<u>CUSIP No. 603170101</u> <u>Schedule 13G</u> <u>Page 8 of 8</u>

**LIST OF EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99 | <u>[Joint Filing Agreement.](exhibit99-schedule13g.htm)</u> |

---

## Ex-99

**Exhibit 99**

**JOINT FILING AGREEMENT**

In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of February 24, 2023.

---

| | |
|:---|:---|
| **BioDiscovery 6 FPCI** | **BioDiscovery 6 FPCI** |
| By: Andera Partners, its management company | By: Andera Partners, its management company |
| By: | /s/ Raphaël Wisniewski |
| Name: | Raphaël Wisniewski |
| Title: | Managing Partner |
| **Andera Partners** | **Andera Partners** |
| By: | /s/ Raphaël Wisniewski |
| Name: | Raphaël Wisniewski |
| Title: | Managing Partner |
| **Raphaël Wisniewski** | **Raphaël Wisniewski** |
| /s/ Raphaël Wisniewski | /s/ Raphaël Wisniewski |
| **Laurent Tourtois** | **Laurent Tourtois** |
| /s/ Laurent Tourtois | /s/ Laurent Tourtois |

---

<br>